• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

印度非维生素K拮抗剂口服抗凝剂（NOACs）使用的专家建议：当前观点与未来方向

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.

作者信息

Singh Balbir, Pai Paresh, Kumar Harish, George Sheeba, Mahapatra Sandeep, Garg Vineet, Gupta G N, Makineni Kiran, Ganeshwala Gaurav, Narkhede Pravin, Naqvi Syed M H, Gaurav Kumar, Hukkeri Mohammed Y K

机构信息

Max Super Speciality Hospital, Saket, New Delhi, India.

Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India.

出版信息

Cardiol Ther. 2022 Mar;11(1):49-79. doi: 10.1007/s40119-022-00254-w. Epub 2022 Feb 8.

DOI:10.1007/s40119-022-00254-w
PMID:35137335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8933593/
Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulation requires the integration of the correct type and dose of oral anticoagulants based on patient characteristic, and therefore therapy needs to be individualized for each patient. Growing scientific evidence from studies on NOACs has led to a better understanding of their benefits and safety. A large amount of available data creates a necessity for an adaptable practical document for the usage of NOACs in India. The current consensus, developed by experts from India, aims to give recommendations on various frequently raised clinical questions with regards to NOACs and its usage. This practical document provides a platform upon which future guidelines, policies, training, and education for the use of NOACs can be tailored.

摘要

非维生素K拮抗剂口服抗凝药（NOACs）是用于预防和治疗静脉血栓栓塞症（VTE）及心房颤动（AF）的一类新型抗凝药物。抗凝治疗需要根据患者特征选择正确类型和剂量的口服抗凝药，因此治疗需要针对每位患者进行个体化。关于NOACs的研究不断增加的科学证据，使人们对其益处和安全性有了更好的理解。大量现有数据使得有必要制定一份适用于印度NOACs使用情况的实用文件。由印度专家制定的当前共识旨在就有关NOACs及其使用的各种常见临床问题给出建议。这份实用文件提供了一个平台，据此可为未来使用NOACs的指南、政策、培训和教育进行量身定制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/cdd40bcf91b7/40119_2022_254_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/35b8167304b2/40119_2022_254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/a53f508dc4e3/40119_2022_254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/329737caebb5/40119_2022_254_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/30080f69d1ab/40119_2022_254_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/39d8568a6c27/40119_2022_254_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/8404633d37b7/40119_2022_254_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/adf126af1f21/40119_2022_254_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/cdd40bcf91b7/40119_2022_254_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/35b8167304b2/40119_2022_254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/a53f508dc4e3/40119_2022_254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/329737caebb5/40119_2022_254_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/30080f69d1ab/40119_2022_254_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/39d8568a6c27/40119_2022_254_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/8404633d37b7/40119_2022_254_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/adf126af1f21/40119_2022_254_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d27/8933593/cdd40bcf91b7/40119_2022_254_Fig8_HTML.jpg

相似文献

1
Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.印度非维生素K拮抗剂口服抗凝剂（NOACs）使用的专家建议：当前观点与未来方向
Cardiol Ther. 2022 Mar;11(1):49-79. doi: 10.1007/s40119-022-00254-w. Epub 2022 Feb 8.
2
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.非维生素K拮抗剂口服抗凝剂用于心房颤动和静脉血栓栓塞的有效性和安全性：一项系统评价和荟萃分析
Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28.
3
New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.新型口服抗凝剂治疗急性静脉血栓栓塞症——一项间接比较的系统评价
Vasa. 2014 Sep;43(5):353-64. doi: 10.1024/0301-1526/a000373.
4
Non-vitamin K antagonist oral anticoagulants and heart failure.非维生素K拮抗剂口服抗凝剂与心力衰竭
Arch Cardiovasc Dis. 2016 Nov;109(11):641-650. doi: 10.1016/j.acvd.2016.08.001. Epub 2016 Nov 8.
5
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.新型口服抗凝药阿哌沙班、达比加群、依度沙班和利伐沙班在静脉血栓栓塞症初始及长期治疗与预防中的比较：系统评价与网状Meta分析
PLoS One. 2015 Dec 30;10(12):e0144856. doi: 10.1371/journal.pone.0144856. eCollection 2015.
6
Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.非维生素K口服抗凝剂与维生素K拮抗剂治疗静脉血栓栓塞性疾病的比较
Expert Opin Pharmacother. 2016 Oct;17(15):2033-47. doi: 10.1080/14656566.2016.1232393.
7
Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.非维生素 K 拮抗剂口服抗凝剂和维生素 K 拮抗剂治疗的心房颤动患者的知识差异。
Kardiol Pol. 2018;76(7):1089-1096. doi: 10.5603/KP.a2018.0069. Epub 2018 Mar 12.
8
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.非维生素K拮抗剂口服抗凝药用于心房颤动
Hematol Oncol Clin North Am. 2016 Oct;30(5):1019-34. doi: 10.1016/j.hoc.2016.05.002.
9
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.口服抗凝剂用于静脉血栓栓塞性疾病的一级预防、治疗和二级预防，以及用于心房颤动的卒中预防：系统评价、网状荟萃分析和成本效益分析。
Health Technol Assess. 2017 Mar;21(9):1-386. doi: 10.3310/hta21090.
10
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.印度心房颤动卒中预防共识指南：重点关注非维生素K口服抗凝剂的实际应用。
Indian Heart J. 2015 Dec;67 Suppl 2(Suppl 2):S13-34. doi: 10.1016/j.ihj.2015.10.380. Epub 2015 Nov 24.

引用本文的文献

1
Evaluation of CHADS-VA Score and Systemic Inflammatory Indexes in Patients with Nonvalvular Atrial Fibrillation: A Case-Control Study.非瓣膜性心房颤动患者CHADS-VA评分与全身炎症指标的评估：一项病例对照研究
J Clin Med. 2025 Jun 29;14(13):4601. doi: 10.3390/jcm14134601.
2
Clinical Care Pathway and Management of Major Bleeding Associated with Nonvitamin K Antagonist Oral Anticoagulants: A Modified Delphi Consensus from Saudi Arabia and UAE.非维生素K拮抗剂口服抗凝剂相关严重出血的临床护理路径与管理：沙特阿拉伯和阿联酋的改良德尔菲共识
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024038. doi: 10.4084/MJHID.2024.038. eCollection 2024.
3

本文引用的文献

1
Assessment of adherence, treatment satisfaction and knowledge of direct oral anticoagulants in atrial fibrillation patients.评估房颤患者的依从性、治疗满意度和直接口服抗凝剂知识。
Br J Clin Pharmacol. 2022 May;88(5):2419-2429. doi: 10.1111/bcp.15180. Epub 2022 Jan 10.
2
Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry.非维生素 K 依赖性口服拮抗剂在卒前和卒后 AF 患者中的超适应证剂量使用：前瞻性多中心柏林心房颤动注册研究的结果。
J Neurol. 2022 Jan;269(1):470-480. doi: 10.1007/s00415-021-10866-2. Epub 2021 Oct 31.
3
Status of oral anticoagulant use in a tertiary center in south India.
印度南部一家三级医疗中心口服抗凝剂的使用情况。
J Postgrad Med. 2024 Apr 1;70(2):69-70. doi: 10.4103/jpgm.jpgm_569_23. Epub 2023 Nov 27.
4
Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding.非维生素 K 口服抗凝剂与质子泵抑制剂联合治疗可改善上消化道出血的风险。
Sci Rep. 2023 Oct 13;13(1):17329. doi: 10.1038/s41598-023-44494-9.
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation.
非维生素K拮抗剂口服抗凝剂的适当剂量对心房颤动患者预防卒中的重要性。
TH Open. 2021 Aug 23;5(3):e353-e362. doi: 10.1055/s-0041-1731777. eCollection 2021 Jul.
4
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.VTE疾病的抗栓治疗：CHEST指南及专家小组报告的第二次更新
Chest. 2021 Dec;160(6):e545-e608. doi: 10.1016/j.chest.2021.07.055. Epub 2021 Aug 2.
5
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.肥胖患者使用直接口服抗凝剂治疗和预防静脉血栓栓塞症：ISTH SSC 抗凝控制小组委员会的最新沟通。
J Thromb Haemost. 2021 Aug;19(8):1874-1882. doi: 10.1111/jth.15358. Epub 2021 Jul 14.
6
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.口服抗凝剂在老年房颤患者中的有效性和安全性。
Heart. 2022 Mar;108(5):345-352. doi: 10.1136/heartjnl-2020-318753. Epub 2021 May 11.
7
Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients With Atrial Fibrillation.肥胖房颤患者预防卒中的直接口服抗凝剂选择
Can J Cardiol. 2021 Sep;37(9):1489-1492. doi: 10.1016/j.cjca.2021.04.004. Epub 2021 Apr 15.
8
Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.不同体重指数类别中房颤患者直接口服抗凝剂的治疗结局。
JACC Clin Electrophysiol. 2021 May;7(5):649-658. doi: 10.1016/j.jacep.2021.02.002. Epub 2021 Mar 31.
9
High Fluctuation Between Anticoagulants, Frequent Off-Label Dosing, and No Difference Concerning Outcomes: Results of a Real-Life Cohort Study.抗凝药物波动大、频繁超适应证用药，但结局无差异：一项真实世界队列研究结果。
Am J Med. 2021 Mar;134(3):e165-e170. doi: 10.1016/j.amjmed.2020.09.018. Epub 2020 Oct 24.
10
Long-term effectiveness and safety of anticoagulation therapy in oldest old, frail people with atrial fibrillation.高龄、虚弱的房颤患者抗凝治疗的长期有效性和安全性。
Eur J Intern Med. 2021 Apr;86:91-97. doi: 10.1016/j.ejim.2021.01.020. Epub 2021 Feb 4.